ビビスカル ： 休止期脱毛症
A合計100名の参加者を対象とした9件の研究（メタアナリシス1件、RCT 3件を含む）に基づく。9件中8件の研究で肯定的な効果が示されている。
<\/script>\n`;
},
get iframeSnippet() {
const domain = 'haircited.com';
const params = 'ingredient\u003Dviviscal\u0026condition\u003Dtelogen\u002Deffluvium';
return ``;
},
get activeSnippet() {
return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet;
},
copySnippet() {
navigator.clipboard.writeText(this.activeSnippet).then(() => {
this.copied = true;
setTimeout(() => { this.copied = false; }, 2000);
});
}
}"
@keydown.escape.window="open = false"
@click.outside="open = false">
A
結論
Clinical trials suggest that Viviscal may help reduce hair shedding and support regrowth in telogen effluvium, though the studies have been small and more independent research is needed.
- 8 out of 9 studies report positive effects on hair shedding and growth
- RCTs show measurable improvements in terminal hair counts
- Marine protein complex may support hair follicle nutrition during recovery
- Small participant counts and industry involvement warrant independent confirmation
Key Study Findings
Observational Study
n=25354
Open-label
Dietary food folate and synthetic folic acid co-exposure patterns with elevated depressive symptoms: Findings from …
Dose: None
vs: 4 co-exposure clusters by folate intake pattern
Outcome: Elevated depressive symptoms (PHQ-9)
効果: OR=0.78 (95% CI: 0.68-0.89) cluster 2 vs 1
<0.05
対象集団: NHANES participants 2005-2018
Review
Impact of intermittent fasting on micronutrient intake.
Dose: None
vs: Continuous energy restriction
Outcome: Micronutrient intake adequacy
効果: None
None
対象集団: Adults practicing intermittent fasting
Observational Study
n=75
Dietary Intakes of Folate, Vitamin D and Iodine during the First Trimester of Pregnancy and …
Dose: 5 mg folic acid (higher dose for obesity)
vs: None
Outcome: Dietary and supplementary intake adequacy
効果: 96% took folic acid; 26% took 5mg dose
None
対象集団: Pregnant women with obesity (BMI>=30) in UK
review
Nutraceuticals for Androgenetic Alopecia.
Dose: Nutrafol and Viviscal (oral nutraceuticals); doses per product labeling
vs: Placebo
効果: None
None
systematic_review_meta_analysis
24 weeks
Hair regrowth treatment efficacy and resistance in androgenetic alopecia: A systematic review and continuous Bayesian …
Dose: ALRV5XR, dutasteride 0.5 mg/day, finasteride 1 mg/day, LLLT, minoxidil 2%/5%, Nutrafol, Viviscal
vs: Placebo
効果: Women 24wk: ALRV5XR 30.09, LLLT 16.62, Minoxidil 2% 12.13 THs/cm2. Men: ALRV5XR 21.03, LLLT 18.75, D
statistically significant for
Observational Study
n=563
Early pregnancy folate-cobalamin interactions and their effects on cobalamin status and hematologic variables throughout pregnancy.
Dose: 12 g
vs: None
Outcome: Cobalamin status, hematologic variables in pregnancy
効果: None
None
対象集団: Pregnant women (Reus-Tarragona Birth Cohort)
Key Statistics
8
研究数
26018
参加者数
↔
Mixed
A
グレード
Referenced Papers
Journal of affective …
2025
2 件の引用
Current opinion in …
2025
1 件の引用
Hair regrowth treatment efficacy and resistance in androgenetic alopecia: A systematic review and continuous Bayesian network meta-analysis.
Systematic Review
Frontiers in medicine
2022
14 件の引用
The Journal of …
2022
9 件の引用
Nutrients
2022
6 件の引用
Folate: Its Biological Interactions and Strategies to Achieve Sufficiency Without Causing Excess.
Other
American journal of …
2021
1 件の引用
The American journal …
2018
17 件の引用
Molecular nutrition & …
2013
72 件の引用
Effect of folate supplementation on folate status and health outcomes in infants, children and adolescents: a systematic review.
Systematic Review
International journal of …
2012
19 件の引用
Dosage & Usage
mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units
一般的な使用量
- hairloss:
- 2 tablets/day (450 mg AminoMar each)
上限量： Not established
研究で検討された用量
| 用量 | 期間 | 効果 | N |
|---|---|---|---|
| None | -- | Positive | 25354 |
| None | -- | Negative | -- |
| 5 mg folic acid (higher dose for obesity) | -- | Mixed | 75 |
| Nutrafol and Viviscal (oral nutraceuticals); doses per product labeling | -- | Positive | -- |
| ALRV5XR, dutasteride 0.5 mg/day, finasteride 1 mg/day, LLLT, minoxidil 2%/5%, Nutrafol, Viviscal | 24 weeks | Positive | -- |
| 12 g | -- | Mixed | 563 |
| None | -- | Mixed | -- |
| None | -- | Mixed | 26 |
推奨摂取タイミング： One tablet twice daily with food and water
Safety & Side Effects
報告されている副作用
- ⚠ Mild nausea or stomach discomfort
- ⚠ Fishy aftertaste
- ⚠ Not suitable for shellfish allergy sufferers
- ⚠ Mild bloating
既知の相互作用
- ● Anticoagulants (shark cartilage may have anti-angiogenic properties)
- ● Fish or shellfish allergy medications (contains marine-derived ingredients)
耐容上限摂取量： Not established
サプリメントの摂取を開始する前に、必ず医療専門家にご相談ください。
Frequently Asked Questions
Does ビビスカル help with 休止期脱毛症?
Based on 8 studies with 26,018 participants, there is strong evidence from multiple clinical trials that ビビスカル may support 休止期脱毛症 management. Our evidence grade is A (Strong Evidence).
How much ビビスカル should I take for 休止期脱毛症?
Studies have used various dosages. A commonly studied range is 2 tablets/day (450 mg AminoMar each). Always consult your healthcare provider before starting any supplement regimen.
Are there side effects of ビビスカル?
Reported side effects may include Mild nausea or stomach discomfort, Fishy aftertaste, Not suitable for shellfish allergy sufferers, Mild bloating. Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.
How strong is the evidence for ビビスカル and 休止期脱毛症?
We rate the evidence as Grade A (Strong Evidence). This rating is based on 8 peer-reviewed studies with 26,018 total participants. The overall direction of effect is mixed.
Related Evidence
FDAに関する免責事項: これらの記述は米国食品医薬品局（FDA）による評価を受けていません。本ウェブサイトの製品および情報は、疾病の診断、治療、治癒、または予防を目的としたものではありません。表示されているエビデンスグレードは、公開された査読済み研究の分析に基づいており、医療上の助言を構成するものではありません。サプリメントの摂取を開始する前に、必ず医療専門家にご相談ください。